Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
Public ClinicalTrials.gov record NCT02203773. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with decitabine or azacitidine and the preliminary efficacy of these combinations. In addition, there is a drug-drug interaction (DDI) sub-study only at a single site, to assess the pharmacokinetics and safety of venetoclax (ABT-199) in combination with posaconazole.
Study identification
- NCT ID
- NCT02203773
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 212 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 5, 2014
- Primary completion
- Jun 15, 2022
- Completion
- Jun 15, 2022
- Last update posted
- May 15, 2023
2014 – 2022
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope /ID# 129718 | Duarte | California | 91010 | — |
| University of California, Davis Comprehensive Cancer Center /ID# 129719 | Sacramento | California | 95817 | — |
| Univ of Colorado Cancer Center /ID# 127859 | Aurora | Colorado | 80045 | — |
| Emory Midtown Infectious Disease Clinic /ID# 129715 | Atlanta | Georgia | 30322 | — |
| Northwestern University Feinberg School of Medicine /ID# 128741 | Chicago | Illinois | 60611-2927 | — |
| The University of Chicago Medical Center /ID# 128742 | Chicago | Illinois | 60637-1443 | — |
| Johns Hopkins University /ID# 129699 | Baltimore | Maryland | 21287 | — |
| Dana-Farber Cancer Institute /ID# 127857 | Boston | Massachusetts | 02215 | — |
| Columbia University Medical Center /ID# 130289 | New York | New York | 10032-3729 | — |
| Duke Cancer Center /ID# 129720 | Durham | North Carolina | 27710-3000 | — |
| University of Texas MD Anderson Cancer Center /ID# 127860 | Houston | Texas | 77030 | — |
| University of Texas MD Anderson Cancer Center /ID# 141581 | Houston | Texas | 77030 | — |
| University of Washington /ID# 129717 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02203773, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2023 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02203773 live on ClinicalTrials.gov.